A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system

Abstract Vortioxetine is an antidepressant approved for the treatment of major depressive disorder (MDD). Given its widespread post-marketing clinical use, it is essential to explore its real-world safety. Reports were extracted from the FDA Adverse Event Reporting System (FAERS) from the third quar...

Full description

Saved in:
Bibliographic Details
Main Authors: Miao Liu, Yang Xia, Wenwen Long, Xiaowen Han, Yu Xiong
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Adverse events
Disproportionality analysis
FAERS
Vortioxetine
Pharmacovigilance
Online Access:https://doi.org/10.1038/s41598-025-13786-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-13786-7

Similar Items